Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- procedure : Hypo-fractionated Radiotherapy
Phase: Phase 2
Ages Eligible For Study:
- Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved. - Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed. - Adult men will be considered. - No life expectancy restrictions will apply. - Performance Status will not be considered. - No requirements for organ or marrow function will be made - Ability to understand and the willingness to sign a written informed consent document.